Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
ine, N,N-dipropyl-[ACD/Index Name]
)ethyl]-N-propyl-1-[German][ACD/IUPAC Name] propanamin
)ethyl]-N-propyl-1-[ACD/IUPAC Name] propanamine
)éthyl]-N-propyl-1-[French][ACD/IUPAC Name] propanamine
- Indole, 3-(2-(dipro
- MFCD01718836[MDL number]
ine free base
ine, free base
ethyl-N-propylpropa[ACD/IUPAC Name] n-1-amine
N,N-Dipropyltryptamine, a psychedelic tryptamine compound and lesser-known analogue of DMT, with similar psychedelic effects. Like DMT it is a partial serotonin receptor agonist.
It is closely related to DMT and is reported to be uniquely similar in its hallucinogenic intensity, albeit with a moderately longer duration and greater unpredictability relative to DMT and other psychedelic tryptamines. DPT was first synthesized in 1950. Human use was first reported in 1973, where it was researched in low doses as an adjunct to therapy for alcoholism.
It has also been researched in high doses to induce peak experiences for terminal cancer patients. It has gained some notoriety for its adoption as the primary sacrament for the “Temple of the True Inner Light” in the United States, a Christian off-shoot organization who believe in the ritual use of psychedelics and refer to them as “the true flesh of God. " DPT is commonly consumed via insufflation or orally.
Many report the experience of insufflation to be very congestive and painful which, with the rapidness of onset, does not give the user much time to acclimate themselves to its powerful effects. It can also be administered intramuscularly or via vaporization after conversion to the freebase form. Smoking the freebase is reported to be the preferred route used by the “Temple of True Inner Light”.
Very little data exists about the pharmacological properties, metabolism, and toxicity of DPT, and it has relatively little history of human usage. It has long been available on the research chemicals market as a legal, grey-market alternative to DMT, and commercially distributed through online vendors. Many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with hallucinogens.
It is highly advised to approach this powerful psychedelic substance with the proper amount of precaution and harm reduction practices when using it.
Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain.
DPT contains two propyl groups carbon chains bound to the terminal amine RN of its tryptamine backbone. DPT has a number of substituted analogs such as 4-HO-DPT or 4-AcO-DPT.
|Avg. Mass||244.3752 Da|
|Monoisotopic Mass||244.193954 Da|
Interactions and Synergies
There are no existing interaction or synergy data for this drug.
|Effects||A psychedelic tryptamine with "a wide range of effects at any particular dose depending on the individual"|
|Marguis Test Result|
DPT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A and 5-HT1A receptor as a partial agonist. The role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.
Relative to psychedelic tryptamines like DMT, DPT is often reported to be similar in its hallucinogenic intensity, albeit with a moderately longer duration and more challenging effects. DPT experiences are often described as a “bizarre”, “unsettling”, and “darker” version of DMT experiences. DPT is reported to be more sensual and physical than DMT and other psychedelics with a corresponding amount of adverse physical effects.
- Spontaneous bodily sensations - The "body high" of DPT is generally more prominent to that of the better known DMT. There is often the sensation of limbs feeling disconnected from the body, a force pinning the body to the surface on which it lay and body tremors which can often make the user feel aware of but not in control of their body.
- Physical autonomy
- Changes in felt bodily form
- Changes in felt gravity - At higher doses, physical feelings of moving through spaces at quick speeds or being completely pinned down are common.
- Abnormal heartbeat
- Increased blood pressure
- Motor control loss
- Muscle contractions
- Excessive yawning
- Pupil dilation
- Increased libido - This effect appears to occur with more regularity and intensity than other psychedelic tryptamines.
- Anxiety & Paranoia
- Conceptual thinking
- Cognitive euphoria & Cognitive dysphoria
- Déjà vu
- Emotionality enhancement
- Feelings of impending doom
- Increased music appreciation
- Increased sense of humor
- Novelty enhancement
- Immersion enhancement
- Personal meaning enhancement
- Memory suppression
- Language suppression
- Personal bias suppression
- Simultaneous emotions
- Spatial disorientation
- Autonomous voice communication
- Multiple thought streams
- Thought disorganization
- Thought loops
- Time distortion
- Drifting (melting, breathing, morphing and flowing)
- After images
- Colour replacement
- Colour shifting
- Environmental patterning
- Scenery slicing
- Symmetrical texture repetition
- Visual haze
DPT visual geometry can be described through its variations as intricate in complexity, both abstract and concrete in form, more digital than organic in feel, choppy and only loosely structured in organization, brightly lit, multicolored in scheme, sharp in its edges, fast in speed, simultaneously smooth and glitching in motion, immersive in depth, and consistent in intensity. At higher doses, it is more likely to result in states of level 8A geometry over level 8B.
DPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic barring DMT and ibogaine. These effects include:
- Machinescapes - These are reported to be more common with DPT than with DMT, which lends to its common description as feeling more "industrial" and futuristic, while DMT visuals can often be described as "ancient" or "earthy" in feel.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - As with DMT, DPT produces high level internal hallucinations at appropriate doses more consistently than most other psychedelics. They are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, non-autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental narrative in their overall theme, with a tendency towards chaotic disorganization and incoherence.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, non-autonomous in controllability, geometry-based in style and typically of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental narrative in their overall theme, with a tendency towards chaotic disorganization and incoherence.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
Many reports indicate that while DPT possesses the raw hallucinogenic power to induce transpersonal states traditionally associated with "classical psychedelics", it does so in a significantly less consistent fashion due to the utter bizarreness and oft-noted "sinister", chaotic, or "forceful" undertones that can be present throughout the experience. What insights it can lead the user to typically occur during the aftermath and integration phase that follows, which shares some qualities of a typical near-death experience.
- Spirituality enhancement
- Existential self-realization
- Perception of predeterminism
- Perception of eternalism
- Perceived exposure to inner mechanics of consciousness
- Unity and interconnectedness
- Li, J. X.; Rice, K.; France, C. P. (2007). "Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity". Behavioural Pharmacology. 18 (4): 283–288. :10.1097/FBP.0b013e3281f19ca0. 1473-5849. 0955-8810. OCLC 22170289. PMID 17551320.
- Grof, S.; Soskin, R. A.; Richards, W. A.; Kurland, A. A. (1973). "DPT as an Adjunct in Psychotherapy of Alcoholics". International Pharmacopsychiatry. 8 (1): 104–115. :10.1159/000467979. 0020-8272. OCLC 1753673. PMID 4150711.
- Richards, W. A.; Rhead, J. C.; Dileo, F. B.; Yensen, R.; Kurland, A. A. (1977). "The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients". Journal of Psychedelic Drugs. 9 (1): 1–10. :10.1080/02791072.1977.10472020. 0022-393X. OCLC 7565359.
- "Temple of the True Inner Light". Retrieved January 9, 2020.
- Fantegrossi, W. E.; Reissig, C. J.; Katz, E. B.; Yarosh, H. L.; Rice, K. C.; Winter, J. C. "Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents". Pharmacology Biochemistry and Behavior. 88 (3): 358–365. :10.1016/j.pbb.2007.09.007. 0091-3057. OCLC 848182005. PMC . PMID 17905422.
- Smith, D. A.; Bailey, J. M.; Williams, D.; Fantegrossi, W. E. (2014). "Tolerance and Cross-Tolerance to Head Twitch Behavior Elicited by Phenethylamine- and Tryptamine-Derived Hallucinogens in Mice". Journal of Pharmacology and Experimental Therapeutics. 351 (2): 485–491. :10.1124/jpet.114.219337. 1521-0103. 0022-3565. OCLC 1606914. PMC . PMID 25271256.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089. 1937-6995. 1556-9039. OCLC 163567183. PMC . PMID 19415589.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
- "Title XLVI: Chapter 893: Drug Abuse Prevention And Control". The 2019 Florida Statutes. The Florida Legislature. Retrieved January 10, 2020.
- "Section 2-204 - Schedule I". Oklahoma Statutes Citationized. Oklahoma Judicial Center. January 11, 2019. Archived from the original on July 9, 2019. Retrieved January 10, 2020.
- 1717 CheMall HE052356
- 1717 CheMall HE363332
- A&J Pharmtech AJ-32671
- AKos AKOS015967123
- Alichem A199007554
- ALK ALG00109839
- Amadis Chemical A833279
- American Custom Chemicals Corp API0016774
- Angene AGN-PC-04XNLY
- Ark Pharm, Inc. AK-77110
- Aurora Fine Chemicals K18.679.752
- BePharm B142340
- BGS International BG01541344
- BGS International BG04263314
- BGS International BG04573556
- Biosynth D-6500
- BOC Sciences 61-52-9
- Cayman Chemical CM147817
- CEG Chemical QC-9045
- ChEMBL CHEMBL1779153
- Chembo Pharma KB-258037
- Chemenu CM147817
- ChemIDplus 000061529
- ChemIDplus 61529
- Chemspace CSC016995038
- Collaborative Drug Discovery 42492
- DiscoveryGate 6091
- eMolecules 976843
- eNovation Chemicals D137386
- EPA DSSTox DTXCID80132338
- Erowid DPT
- FDA UNII - NLM S7272VWU50
- Finetech Industry FT-0629586
- iChemical EBD16201
- LabNetwork LN02166701
- LeadScope LS-83046
- Mcule MCULE-7107739457
- NIAID 517295
- NIST Spectra mainlib_334908
- OXchem AX8142340
- PubChem 6091
- PubMed 15516287
- PubMed 17223101
- PubMed 17905422
- Rosewachem RW094300
- Royal Society of Chemistry b008715g
- Royal Society of Chemistry b203057h
- Royal Society of Chemistry c1cp20420c
- RSC Learn Chemistry Wiki N,N-Dipropyltryptamine
- Springer Nature Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
- Springer Nature Effects of phencyclidine and stress on plasma creatine phosphokinase (CPK) and aldolase activities in man
- Springer Nature Effects of psychotropic drugs on open-field behaviour in rats
- Springer Nature Serum CPK and aldolase activity in man following controlled administration of psychotomimetic drugs
- Springer Nature Simultaneous determination of tryptamine analogues in designer drugs using gas chromatographyu2013mass spectrometry and liquid chromatographyu2013tandem mass spectrometry
- Thomson Pharma 00513944
- Tractus Company Limited
- Wikidata Q2723010
- Wikipedia Dipropyltryptamine
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.